Hope you size your positions accordingly. The risk/reward appears poor as there's little upside but alot of downside risk. Not saying will happen but biotech one trick ponies are prone to spectacular implosions wiping out shareholder lifesavings. Don't say you didn't see it coming.
74% of stock is owned by inst. We are to believe you know more than the experts, think not! Do you own any shares? Why are you here? Trying to save us? Don't think so! How many shares have you shorted? A--H---!
These adverse events are in the label and impossible to tell whether they are from the sickest pts. Cancer pts in general have all sorts of complications. Bringing up AFFY a company with a drug that has nothing in common with ponatinib is silly.